Skeletal muscle mitochondria of NDUFS4−/− mice display normal maximal pyruvate oxidation and ATP production  by Alam, Mohammad T. et al.
Biochimica et Biophysica Acta 1847 (2015) 526–533
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r .com/ locate /bbab ioSkeletal muscle mitochondria of NDUFS4−/−mice display normal
maximal pyruvate oxidation and ATP productionMohammad T. Alam a,b,1,2, Ganesh R. Manjeri a,b,2, Richard J. Rodenburg b,c, Jan A.M. Smeitink b,c,
Richard A. Notebaart b,d, Martijn Huynen b,d, Peter H.G.M. Willems a,b, Werner J.H. Koopman a,b,⁎
a Department of Biochemistry, RIMLS, Radboud University Medical Center, Nijmegen, The Netherlands
b Centre for Systems Biology and Bioenergetics, Radboud University Medical Centre, Nijmegen, The Netherlands
c Department of Pediatrics, NCMD, Radboud University Medical Center, Nijmegen, The Netherlands
d Centre for Molecular and Biomolecular Informatics, RIMLS, Radboud University Medical Center, Nijmegen, The NetherlandsAbbreviations: Δψ, mitochondrial membrane potent
transport chain; KO, knockout; IMS, inter-membrane sp
membrane;MOM,mitochondrial outer membrane; ODE,
OXPHOS, oxidative phosphorylation;WT,wild-type
⁎ Corresponding author at: 286 Biochemistry, Radbo
Sciences (RIMLS), Radboud University Medical Center (R
HB Nijmegen, The Netherlands. Tel.: +31 24 3614589; fa
E-mail addresses:mta26@cam.ac.uk (M.T. Alam), Gan
(G.R. Manjeri), Richard.Rodenburg@radboudumc.nl (R.J. R
Jan.Smeitink@radboudumc.nl (J.A.M. Smeitink), Richard.N
(R.A. Notebaart), Martijn.Huijnen@radboudumc.nl (M. Hu
Peter.Willems@radboudumc.nl (P.H.G.M. Willems), Wern
(W.J.H. Koopman).
1 Current address: Dept. of Biochemistry, 80 Tennis Co
1GA, Cambridge, United Kingdom.
2 First authorship contribution: These authors equally c
http://dx.doi.org/10.1016/j.bbabio.2015.02.006
0005-2728/© 2015 Elsevier B.V. All rights reserved.a b s t r a c ta r t i c l e i n f oArticle history:
Received 13 August 2014
Received in revised form 3 February 2015
Accepted 7 February 2015
Available online 14 February 2015
Keywords:
CI, complex I
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ETC, electron transport chainMitochondrial ATPproduction ismediated by the oxidative phosphorylation (OXPHOS) system,which consists of
four multi-subunit complexes (CI–CIV) and the FoF1-ATP synthase (CV). Mitochondrial disorders including Leigh
Syndrome often involve CI dysfunction, the pathophysiological consequences of which still remain incompletely
understood. Here we combined experimental and computational strategies to gain mechanistic insight into the
energy metabolism of isolated skeletal muscle mitochondria from 5-week-old wild-type (WT) and CI-deﬁcient
NDUFS4−/− (KO) mice. Enzyme activity measurements in KO mitochondria revealed a reduction of 79% in
maximal CI activity (Vmax), which was paralleled by 45–72% increase in Vmax of CII, CIII, CIV and citrate synthase.
Mathematical modeling of mitochondrial metabolism predicted that these Vmax changes do not affect the
maximal rates of pyruvate (PYR) oxidation and ATP production in KO mitochondria. This prediction was
empirically conﬁrmed by ﬂux measurements. In silico analysis further predicted that CI deﬁciency altered the
concentration of intermediate metabolites, modestly increasedmitochondrial NADH/NAD+ ratio and stimulated
the lower half of the TCA cycle, including CII. Several of the predicted changes were previously observed in
experimental models of CI-deﬁciency. Interestingly, model predictions further suggested that CI deﬁciency
only has major metabolic consequences when its activity decreases below 90% of normal levels, compatible
with a biochemical threshold effect. Taken together, our results suggest thatmouse skeletalmusclemitochondria
possess a substantial CI overcapacity,whichminimizes the effects of CI dysfunction onmitochondrialmetabolism
in this otherwise early fatal mouse model.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
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ontributed to the study.outer membrane (MOM), with in between an inter-membrane space
(IMS) [1–9]. Mitochondrial ATP production is fueled by pyruvate
(PYR), two molecules of which are generated from glucose (GLU) by
glycolysis in the cytosol. PYR can be reversibly converted by lactate de-
hydrogenase (LDH) into lactate or imported into themitochondrial ma-
trix by a dedicated pyruvate carrier [10].Within themitochondrion PYR
is converted into acetyl coenzyme A (acetyl-CoA) that enters the tricar-
boxylic acid (TCA) cycle to yield two molecules of CO2, one molecule of
ATP, four molecules of NADH and one molecule of FADH2. NADH and
FADH2 serve as substrates for the oxidative phosphorylation (OXPHOS)
system to generate ATP [2,5]. The OXPHOS system consists of four
multi-subunit complexes (CI–CIV) that form the electron transport
chain (ETC) and the ATP-generating FoF1-ATPase (CV). Within the ETC.
electrons donated by NADH (at CI) and FADH2 (at CII) are transported
to CIII and CIV by coenzyme Q10 (CoQ10) and cytochrome-c (cyt-c), re-
spectively. At CIV, electrons are donated to molecular oxygen (O2) to
form water. The energy released during electron transport is utilized
at CI, CIII and CIV to transport H+ out of themitochondrialmatrix across
the MIM. This process generates an inward-directed proton-motive
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(ΔpH). At CV the energy associatedwithH+ re-entry into themitochon-
dria matrix is used to generate ATP from ADP and inorganic phosphate
(Pi).
In addition to ATP generation, mitochondria play a key role in vari-
ous other cellular processes, including reactive oxygen species (ROS)
generation, calcium signaling and apoptosis induction. Therefore it is
not surprising that dysfunction of the OXPHOS system, which sustains
most mitochondrial functions, is associated with a broad range of
human disorders [11–17]. Among OXPHOS disorders, deﬁciency of CI
(OMIM 252010) is the most common [18–26]. Human CI deﬁciency is
associated with a wide range of clinical presentations including muscle
weakness, heart disease, liver failure, respiratory failure and congenital
lactic acidosis, often leading to death in early childhood [11,21,24–27].
CI is the largest protein complex of the oxidative phosphorylation
system and consists of 44 different proteinaceous subunits that
are encoded by either the mitochondrial (mtDNA) or nuclear DNA
[28–30]. Regarding the cellular consequences of nDNA-encoded CI
mutations, several studies with primary patient ﬁbroblast have been
carried out revealing aberrations in maximal ETC. enzyme activities
(Vmax) andmitochondrial morphology, increased levels of cellular reac-
tive oxygen species (ROS) and disturbed calcium and ATP homeostasis
[28,31–36].
Recently a whole-body KOmouse model of human CI deﬁciency be-
came available inwhich one of the CI accessory subunit genes (NDUFS4)
is deleted [24]. The NDUFS4 gene encodes an 18-kDa protein (NDUFS4
or NADH dehydrogenase (ubiquinone) Fe-S protein 4). When NDUFS4
is absent, proper CI assembly is hampered and its Vmax is reduced [20,
21,23,24,26,37,38]. Importantly, several symptoms of human CI deﬁ-
ciency are also observed in NDUFS4−/− animals such as developmental
delays, failure to thrive, lethargy, opthalmoplegia and progressive en-
cephalomyopathy leading to early lethality. However, the consequences
of NDUFS4 gene deletion on mitochondrial energy metabolism, its
underlying reaction rates and reactant concentrations have not been in-
vestigated yet. Here we addressed this question by combining experi-
mental and computational strategies to evaluate: (i) if NDUFS4
knockout affected the Vmax of key ETC enzymes and citrate synthase
(CS), and (ii) whether NDUFS4 knockout impacted on the maximal
rates of PYR oxidation and ATP production in isolated skeletal muscle
mitochondria. To this end we ﬁrst adapted a previously validated dy-
namic model of mitochondrial metabolism [39] to our experimental
conditions. Next, we used this model to predict the consequences of
NDUFS4 knockout on the steady-state values ofmetabolicﬂuxes,metab-
olite concentrations and physiological variables includingΔψ. This anal-
ysis predicted that a reduction of ~80% in theVmax of CI did not affect the
maximal rates of mitochondrial PYR oxidation and ATP production in
isolated NDUFS4−/− skeletal muscle mitochondria. This prediction was
conﬁrmed by experimental ﬂux analysis and suggests that these mito-
chondria possess a substantial CI overcapacity that limits the impact of
CI deﬁciency on mitochondrial metabolism.
2. Materials and methods
2.1. Animals
NDUFS4−/− knockout (KO) and wild-type (WT) mice (mixed 129/
Sv: C57BL6 background) were generated by crossing heterozygote
(NDUFS4+/−) mice. The genotype was conﬁrmed by polymerase chain
reaction (PCR) testing. Mice had ad libitum access to food and water
and were fed on a standard animal diet (Ssniff GmbH, Soest,
Germany: V1534-300 R/M-H). Animals were group housed at 22 °C
and maintained on a day and night rhythm of 12 h. The animal studies
were approved by the Regional Animal Ethics Committee (Nijmegen,
The Netherlands) and performed under the guidelines of the Dutch
Council for Animal Care. Both male and female animals were used in
this study yielding similar results.2.2. Measurement of maximal pyruvate oxidation, ATP production and
enzymatic activities in mitoplasts
Skeletal muscle tissue from the entire hind limb was harvested from
5-week-old WT and KO animals, homogenized and centrifuged at
600 g. Importantly, maximal PYR oxidation rates, ATP production rates
and enzymatic activities (Vmax) were determined using the same 600 g
supernatant using standardized protocols [40,41]. To quantify pyruvate
oxidation, mitochondrial preparations were incubated with radiolabeled
substrate ([1-14C] pyruvate). After 20 min the reaction was stopped and
the amount of liberated radioactive CO2 (14CO2) was quantiﬁed [40]. The
assay medium (pH 7.4) contained K+-phosphate buffer (30 mM; source
of Pi), KCl (75mM), Tris (8mM), K-EDTA (1.6mM), P1,P5-Di (adenosine-
5′) pentaphosphate (Ap5A; 0.2 mM), MgCl2 (0.5mM), ADP (2mM), cre-
atine (20 mM), malate (1 mM) and [1-14C] pyruvate (1 mM). AP5A is a
potent adenylate kinase (AK) inhibitor required to prevent interference
of the AK reactionwith the levels of produced ATP, aswell aswith the ex-
cess of ADP required for this assay. For ATP production measurements,
the same assay medium was used but with pyruvate instead of [1-14C]
pyruvate. After 20 min, the reaction was stopped by addition of 0.1 M
HClO4. The reaction mixture was centrifuged at 14,000 g for 2 min at
2 °C. To the supernatant, 1.2 vol (V/V) of 0.333 M KHCO3 was added,
and thismixturewas diluted 2-fold. The amount of ATP and phosphocre-
atine formed during the reactionwasmeasured in the supernatant using
a Konelab 20XT auto-analyzer (Thermo Scientiﬁc). Mitochondrial ATP
production rate was corrected using a parallel assay in which residual
glycolysis was blocked by arsenite (2 mM) [40]. The maximal activities
of complex I (CI), complex II (CII), complex III (CIII), complex IV (CIV)
and citrate synthase (CS) were measured in freeze-thawed 600 g super-
natants, as described in [41].
2.3. Mathematical modeling and statistical analysis
Dynamic modeling and statistical analysis were performed using
custom scripts written in Matlab 6.1 (Mathworks, Natick, Massachu-
setts, U.S.A.). The latter are available upon request. Unless stated other-
wise, experimental data is presented asmean± SEM (standard error of
the mean) and statistical signiﬁcance between datasets is assessed
using an independent 2-population Student's t-test.
3. Results & discussion
3.1. Overall experimental and computational strategy
In this study we used mitochondria from skeletal muscle of
wildtype (WT) mice and NDUFS4−/− (KO) mice for experimental
analysis. Mitochondria were placed in an assay medium and were
considered as a classical input–output (I/O) system (cartoon in
Fig. 1), which converts pyruvate (PYR; input) into ATP (output) via
the integrated action of transporters, the TCA cycle and the
OXPHOS system (Fig. 2). To perform computational analysis of this
system we adapted a mathematical model of the mitochondrial bioen-
ergetic system that was previously validated by Beard and co-workers
[39]. This model consists of a collection of ordinary differential equa-
tions (ODEs) and parameters, which allows integrated simulation of
the above I/O system and prediction of the underlying ﬂuxes, metabo-
lite concentrations and physicochemical parameters. Our overall strate-
gy (Fig. 1) aimed to ﬁrst adapt the published model to the conditions
underwhich PYRoxidation andATPproduction aremeasured in our ex-
perimental assay medium (explained in more detail below). This
yielded a mathematical model for isolated WT mitochondria (“WT
model”). Next, theWTmodelwas adjusted by including information re-
garding the measuredmaximum activities (Vmax) of CI, CII, CIII, CIV and
citrate synthase (CS) in mitochondria fromWT and KO mice. This was
achieved bymultiplying the Vmax values in theWTmodel by a “pre-fac-
tor” (KO/WT) corresponding to the experimentally observed change in
TCA
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Fig. 1. Overall experimental and computational strategy. A mathematical model of mitochondrial metabolism developed by Beard and coworkers [39] was adapted to match our
experimental conditions. This yielded amodel for isolatedmitochondria from skeletal muscle of wild-type mice (WTmodel). By including experimental data, theWTmodel was adapted
to create various KO models (A, B and C) for simulating mitochondrial metabolism in isolated muscle mitochondria from NDUFS4−/− (KO) mice with isolated complex I deﬁciency.
Predicted PYR oxidation and ATP consumption rates were compared with experimental ﬂux measurements for model validation and predictive analysis (see main text for details).
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ed an increase in Vmax for the KO vs. the WT condition, whereas a pre-
factor b1 represented a decrease in Vmax for the KO vs. the WT condi-
tion. We also generated two alternative KO models (KO model B and
C) to simulate the consequences of increased CS activity with respect
to TCA cycle enzyme activity and mitochondrial volume (see below
for details). The KO models were used to predict the maximal PYR oxi-
dation and ATP production rates (expressed as KO/WT ratios), which
were compared with experimentally determined values for model val-
idation, as well as other relevant reaction ﬂuxes, metabolite concentra-
tions and physiological parameters.
3.2. WT model
The model of Beard et al. [39] consists of three compartments
(mitochondrialmatrix, inter-membrane space and buffer space) and in-
corporates 43 ﬂux expressions including TCA cycle ﬂuxes, OXPHOS
ﬂuxes, substrate and cation ﬂuxes, passive permeation ﬂuxes and buffer
reaction ﬂuxes (Fig. 2). This model also contains various TCA control
pathways including regulation of pyruvate dehydrogenase (PDH), α-
ketoglutarate dehydrogenase (α-KGDH), aconitase (ACO) and fumarase
(FUM; for a full list see Table 2 in [39]). All reactions in the model are
thermodynamically balanced, and its parameters are validated using
experimental data [39,42–46]. To generate the WT model we ﬁrstremoved metabolites, reactions and constant state variables from the
Beard model that were not relevant under our experimental conditions
(see Supplement for full details). These include two ATP-consuming re-
actions in the buffer space (i.e., hexokinase and adenylate kinase), one
reaction for passive AMP permeation, one adenylate kinase reaction in
the inter-membrane space, and two substrate transport reactions
(isocitrate and fumarate transport). Next, variousmetabolite concentra-
tions were adapted to match the conditions of our experimental assay
(e.g., [PYR] = 1 mM, [Pi] = 30 mM, [malate] ([MAL]) = 1 mM,
[ATP] = 0 mM, [ADP] = 2 mM; a full list is provided in Supplementary
Table S2). The ﬁnal WTmodel consisted of 46 state variables (including
Δψ) and 37 ﬂux expressions. Analysis of this model at steady-state (i.e.,
compatible with the experimental conditions of the PYR and ATP ﬂux
assays) yielded predictions of various ﬂuxes, reactant concentrations
and derived variables for the WT situation (Fig. 2A).3.3. Experimental analysis of ETC. complex and citrate synthase in isolated
skeletal muscle mitochondria from KO mice
The Vmax of CI was reduced by 79% in KO vs. WT mitochondria
(Table 1; “Experimental data, Vmax values”). This reduction in CI activity
was paralleled by a 45–72% increase in Vmax of the other ETC. enzymes
and of the TCA-cycle enzyme citrate synthase (CS).
529M.T. Alam et al. / Biochimica et Biophysica Acta 1847 (2015) 526–5333.4. KO models
To create KOmodel A, the Vmax values for CI, CII, CIII, CIV and CS in the
WT model were multiplied by the fractional change in this parameter in
KO vs. WT (Table 1: “Parameters in the model”). The predictions of KO
model A at steady-state are summarized in Fig. 2B. Interestingly, although
CI activitywas reducedby79% inKOmusclemitochondria themodel pre-
dicted no change in the maximal PYR oxidation (input of the system) or
ATP production (Table 1; “Predicted by the model, Flux values”). The lat-
terwas conﬁrmed by experimental analysis (Table 1; “Experimental data,
Flux values”). The lack of effect of NDUFS4−/− knockout on PYR and ATP
ﬂuxes might relate to the fact that mitochondria were isolated from 5-
week-old KO mice. At this age the pathophysiological phenotype of the
NDUFS4 gene deletion is still relatively mild [24].
Maximal CS activity was 1.72 higher in KO than inWTmitochondria.
This might reﬂect a general increase in TCA-cycle enzyme level/activity
and/or an increase in mitochondrial volume (e.g., [45]). To explore the
potential effect of such changes on PYR and ATP ﬂuxes in KOmitochon-
dria we generated two additional KO models (KO model B and C). KO
model B was derived from KO model A by increasing the activity of all
TCA cycle enzymes by a “CS factor” of 1.72. KO model C was derived
from KO model A by increasing the Vmax of all other enzymes/trans-
porters in the model and mitochondrial volume by the CS-factor of
1.72. KO model B correctly predicted the lack of change in PYR and
ATP ﬂuxes, whereas KO model C predicted that these ﬂuxes should be
59–69% higher in KO than in WT mitochondria (Table 1). This suggests
that the increase in CSmaximal activity might reﬂect a general increase
in the level of TCA enzymes but cannot be considered a measure of mi-
tochondrial volume.
3.5. Metabolic changes in skeletal muscle mitochondria from KO mice
Comparing the predictions of the WT model (Fig. 2A) and those of
KOmodel A (Fig. 2B) highlighted changes in the TCA cycle andmetabo-
lite transport system. Interestingly, the TCA cycle was divided into an
“upper” and “lower” segment deﬁned by its reaction ﬂuxes (Fig. 2B;
lower segment colored green). To the best of our knowledge such a bi-
furcation of the TCA cycle was not reported previously in CI deﬁciency.
The upper segment consists of reactions of citrate synthase (CS),
aconitase (ACO), isocitrate dehydrogenase (ICDH) andmalate dehydro-
genase (MDH). The lower segment consists of α-ketoglurarate dehy-
drogenase (α-KGDH), succinyl-CoA synthetase (SCS), succinate
dehydrogenase (CII) and fumarase (FUM). In the upper TCA segment,
WT steady-state reaction ﬂuxes were more than 3-fold higher than
those within the lower segment (Fig. 2A). In the WT case, the ﬂux
through ICDH ﬂux (0.89 mM/s) gets divided at the end of the upper
half segment of the TCA cycle: 69% of the ﬂux (0.61 mM/s) goes out of
the mitochondrial matrix to the IMS via the α-ketoglurarate (α-KG)/
malate (MAL) antiporter (AKM) mechanism. The latter reaction is also
the most active among the three antiporter mechanisms that bring
MAL into the mitochondrial matrix to participate in the initial part of
the upper segment of the TCA cycle. Utilizing this ﬂux, the upper TCA
segment, along with pyruvate dehydrogenase (PDH) generates 3
NADH molecules to fuel CI (Fig. 2A). The remaining part (31%) of the
ICDH ﬂux goes to α-KGDH (0.27 mM/s) to enter the lower half of the
TCA cycle to fuel CII and also produce 1 ATP and 1 NADH molecule.
The two remaining antiport mechanisms for MAL entry into the TCA
cycle are the citrate (CIT)/malate (MAL) antiporter (CM) and the succi-
nate (SUC)/malate (MAL) antiporter (SM). Together, CM and SM only
contribute 0.5% to the totalMAL entry to thematrix (Fig. 2A). Fig. 2A fur-
ther shows that inWTmitochondria the upper and lower TCA segments
mainly provide substrates to CI and CII, respectively. Obviously, the
combined action of CI and CII then provides electrons to the other ETC.
complexes to sustain the PMF and fuel ATP generation by CV. Of note,
a substantial part of the entering PYR does not contribute to ATP pro-
duction. Every PYR produces 4 NADH after entering the TCA cycle. ATPproduced per NADH oxidized, which is same as ATP produced per O2
consumed, can be calculated simply by dividing the CV ﬂux by the CIV
ﬂux. For theWTmice CV/CIV= 7.09/3.20= 2.22. According to this cal-
culation we should have obtained 363 ∗ 4 ∗ 2.22 = 3223 nmol/h/mg
protein ATP, which is 45% higher than the observed ATP ﬂux (Table 1).
In the KO mice, the expected ATP production rate is 391 ∗ 4 ∗ (7.03 /
3.19)= 3447 nmol/h/mg protein, which is 65% higher than the experi-
mental value. The lower rate of observed vs. predicted ATP production
may be due to the absence in themodel of other PYR-consumingmech-
anisms, for instance conversion into lactate (LAC). In addition to the
above, analysis of the KO model suggested various changes in other re-
action ﬂuxes andmetabolite concentrations (Fig. 2B). In the CI-deﬁcient
state the lower segment of the TCA cycle carried 10–11%more ﬂux than
theWTmodel. Also the ICDH ﬂux distribution to the lower segment and
to the antiport mechanism was altered in the KO model. Of the ICDH
ﬂux, 35% is diverted towards the lower segment (31% in WT) and 65%
towards the AKM system (69% inWT) to transport MAL into thematrix.
Reducing CI activity by 80% only marginally affected its ﬂux. It was also
predicted that the ﬂux through the upper part of the TCA cycle was only
slightly reduced in KOmitochondria. This reduction is compensated by
an increase (11%) in ﬂux through the lower part of the TCA cycle,
explaining the absence of effect on the total mitochondrial ATP produc-
tion rate. The KO model further predicted a change in the steady-state
matrix concentration of intermediate metabolites (Fig. 2B). Our predic-
tions are compatible with the results of Mazat et al. [46], where a reduc-
tion in ETC. complex activity only slightly affected the ﬂuxes of these
complexes but major changes occurred in the concentration of metabo-
lites associated with the affected complexes. With respect to CI, the KO
model predicts a reduction in its upstream metabolite (reduced
ubiquinol;“QH2” or ubiquinol: decreased by 65%) and an increased in
its downstream metabolite (oxidized ubiquinol; “COQ”or ubiquinone:
increased by 11%). Compatible with the measured increase in Vmax of
CII and CIII in KO mitochondria, the KO model predicts a decrease in
the concentration of intermediate metabolites downstream of these
complexes (i.e., succinate and reduced cytochrome-c were down by
71% and 26%, respectively). Similarly, the increased Vmax of CIII in the
KO model was associated with an increase in its upstream metabolites
oxidized ubiquinol (‘COQ’; by 11%) and oxidized cytochrome-c (“Cox”;
by 13%). Mitochondrial NADH/NAD+ ratio and Δψ were predicted to
be (slightly) increased and depolarized, respectively. The latter predic-
tions are compatible with results obtained in patient ﬁbroblasts with
inherited CI deﬁciency and cells treated with the CI inhibitor rotenone
[28,47].
3.6. Predicting the consequences of CI deﬁciency
Patients with isolated CI deﬁciency display a variably reduced CI ac-
tivity (Vmax) in muscle homogenates and primary ﬁbroblasts [38]. Dur-
ing the last years, the consequences of isolated CI deﬁciency in primary
patient ﬁbroblasts have been extensively studied at the cellular level
[28,31–34]. Native gel electrophoresis revealed variable amounts of
holo-CI in patient cells, where in general three patterns were observed
(i) the amount of active holo-CI was reduced (mutations in NDUFS2,
NDUFS7 or NDUFS8) (ii) the amount of active holo-CI was reduced
and a ~830-kDa CI was present (NDUFV1, NDUFS1) (iii) or only a
~830-kDa CI was present (NDUFS4) [48,49]. Analysis of total cell ho-
mogenates by Western blotting revealed that the level of the 39-kDa
CI subunit was twofold reduced in patient cohorts as compared to the
controls, however cellular expression levels of other OXPHOS complex
subunits were not altered signiﬁcantly [33]. To gain further insight
into the metabolic consequences of CI activity reduction at steady-
state we performed various simulation runs with the WT model using
different Vmax values for CI (i.e., lowering it from 100% to 1% of its nor-
mal maximal activity). A complete overview of the numerical data gen-
erated by these simulations (i.e., steady-state reaction ﬂuxes,metabolite
concentrations and physiological parameters) is provided in
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patible with a CI activity of 0%, which resulted in all ﬂuxes being zero.
The relationship between residual CI activity and key variables in the
model is summarized in Fig. 3. Most of the ﬂuxes of the OXPHOS com-
plexes (Fig. 3A), TCA cycle (Fig. 3B) and trans-MIM exchangers
(Fig. 3C) were not altered by moderate CI activity reduction. As
discussed above, the CII ﬂux increased with decreasing CI activity
(Fig. 3A), compatible with the predicted activation of the lower half of
the TCA cycle (Fig. 3B).H
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Table 1
Maximal mitochondrial enzyme activities, pyruvate oxidation and ATP production in isolated skeletal muscle mitochondria fromWT and KO mice.
Vmax values Experimental data Parameters in the model
WT KO KO/WT KO model A KO model B KO model Ca
CI (mU/mg)d 34 ± 7.2 7.2 ± 2.0⁎ 0.21 Vmax × 0.21 Vmax × 0.21 Vmax × 0.21
CII (mU/mg)d 36 ± 4.9 56 ± 6.3⁎ 1.56 Vmax × 1.56 Vmax × 1.56 Vmax × 1.56
CIII (mU/mg)d 278 ± 39.4 404 ± 45.2 1.45 Vmax × 1.45 Vmax × 1.45 Vmax × 1.45
CIV (mU/mg)d 257 ± 54.6 437 ± 34.9⁎ 1.7 Vmax × 1.70 Vmax × 1.70 Vmax × 1.70
CS (mU/mg)d 227 ± 44.3 390 ± 32.2⁎ 1.72 Vmax × 1.72 Vmax × 1.72 Vmax × 1.72
TCA cycle enzymesb n.d. n.d. n.d. Like in WT model Vmax × 1.72 Vmax × 1.72
Transport reactionsc n.d. n.d. n.d. Like in WT model Like in WT model Vmax × 1.72
Flux values Experimental data Predicted by the model
PYR oxidation (nmol/h/mg)d 363 ± 52.7 391 ± 113 1.08 KO/WT= 0.97 KO/WT= 0.94 KO/WT= 1.59
ATP production (nmol/h/mg)d 1776 ± 251.7 1532 ± 326.3 0.86 KO/WT= 1.00 KO/WT= 1.00 KO/WT= 1.69
Abbreviations: CI, complex I; CII, complex II or succinate dehydrogenase (SDH); CIII, complex III; CIV, complex IV; CS, citrate synthase; KO, knockout; Vmax,maximal activity;WT,wild type.
Statistics: Average values were obtained from 5 individual animals.
a Inmodel C also theVmax of CV andNDPK (Fig. 2) are increased by a factor of 1.72. In the lattermodel also the Vmax of GOT (Glutamate oxaloacetate transporter), GLUH (Glutamate/H+-
cotransporter), AG (Aspartate/Glutamate-antitransporter), GLUT (Glutamate exchanger), ASPt (Aspartate exchanger), MALP (Malate/Phosphate antitransporter) and KH (K+/H+-
antiporter) were increased by a factor of 1.72. However, the reactions involving these enzymes/transporters are not in Fig. 2 because their predicted ﬂux equals zero.
b All enzymes participating in the TCA cycle in addition to CII and CS (i.e., PDH, ACO, ICDH, α-KGHD, SCS, FUM and MDH; Fig. 2).
c All transport reactions across the mitochondrial inner and outer membrane (i.e., ANT, AKM, CM, HL, HP, PYRH, SM, EX1, EX2, EX3, EX4, EX5, EX6, EX7, EX8; Fig. 2).
d Normalized on mg protein.
⁎ (P b 0.05) relative to WT.
531M.T. Alam et al. / Biochimica et Biophysica Acta 1847 (2015) 526–533This suggests that steady-state energy homeostasis under non
substrate-limited conditions is not affected as long as a certain (critical)
amount of residual CI activity remains. In other words, CI activity can be
inhibited to a certain threshold value (in our case near to 90% inhibition)
before its metabolic consequences become. Similar observations were
made in various rotenone-treated rat tissues, where mitochondrial O2
consumption substantially dropped only when CI was inhibited by
more than 80% [46,52,53]. Overcapacity of OXPHOS complexes is not
speciﬁc for CI [46,50]. For instance, a reduction in CIV activity by almost
50% was virtually without effect on CIV ﬂux and O2 consumption in pa-
tient cells [46,54].
Metabolic control analysis (MCA) of theWTmodel revealed that the
control coefﬁcient for CI equaled 0.013, which was lower than a previ-
ously reported value ([50]). Our model also predicted control coefﬁ-
cients for CII, CIII, CIV and CV (see Supplementary Fig. S1) that were
lower than previously reported values [50]. In general, lower control co-
efﬁcients are associated with a higher threshold value [46,51]. In this
sense, the high CI threshold value predicted by our model might be
overestimated. This could be due the fact that although the original
modelwas parametrized using experimental data [39], itwas not a skel-
etal muscle-speciﬁc model. Compatible with previous results in genetic
and inhibitor-induced ﬁbroblast models of CI deﬁciency [25,28,38], the
WT model predicted that a reduction in CI activity was associated
with redox alterations (e.g., an increase in NADH/NAD+ ratio; Fig. 3H)
and partial Δψ depolarization (Fig. 3I).
4. Summary and conclusion
This study combines experimental and in silico strategies to gain in-
sight into the consequences of isolated mitochondrial CI deﬁciency inFig. 2. Predicted metabolic consequences of mitochondrial complex I deﬁciency in isolated mo
dium (gray) for experimental analysis. This was modeled using the depicted metabolic networ
(OXPHOS) system. Numerals represent the predicted steady-state values of ﬂuxes (in mmol s−
mM) for theWT situation. (B) Similar to panel A, but now formitochondria fromNDUFS4−/− (K
(red) or not affected (white) in the KOmodel. Abbreviations: ACCOA, acetyl-CoA; ACO, aconita
ANT, adenine nucleotide translocase; ATP, adenosine triphosphate; CI, complex I; CII, complex
kinase; CM, citrate (CIT)/malate (MAL) antiporter; COQ, oxidizedubiquinol; Cox, oxidized cytoc
EX1, ADP exchange with assay medium; EX2, α-KG exchange with assay medium; EX3, ATP e
with assay medium; EX6, Pi exchange with assay medium; EX7, PYR exchange with assay med
nosine diphosphate; GTP, guanosine triphosphate; H+, hydrogen; HL, H+-leak; HP, H+-Pi cotra
hydrogenase; NAD+, nicotinamide adenine dinucleotide; NADH, reduced NAD+; NDPK, nucle
phosphate; PYR, pyruvate; PYRH, PYR-H+ cotransporter; QH2, reduced ubiquinol; SCOA, suc
SUC, succinate; α-KG, α-ketoglutarate; α-KGDH, α-ketoglurarate dehydrogenase; Δψ, mitochoisolated skeletal muscle mitochondria from NDUFS4−/−mice. We dem-
onstrate thatNDUFS4−/− gene deletion reducesmaximal CI activity and
is paralleled by increased activity of CII, CIII, CIV and CS. Surprisingly,
NDUFS4 knockout did not affect the maximal rate of PYR oxidation
and ATP production. Mathematical modeling suggests that this phe-
nomenon might be due to increased activity of the lower half of the
TCA cycle, including CII. It further appears that mouse skeletal muscle
mitochondria possess a substantial CI overcapacity, which further min-
imizes the effects of partial CI deﬁciency on mitochondrial metabolism.
This means that CI activity can be inhibited to a certain threshold value
(in our case near to 90% inhibition) before its metabolic consequences
become apparent. We conclude that these consequences in CI-deﬁcient
KOmitochondria areminimized by CII-mediated fueling of the OXPHOS
system and CI overcapacity. This still leaves open the possibility thatmi-
tochondrial ATP generation becomes limited when energy substrates
are scarce and/or cellular energy demands increase during cell
activation.
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Fig. 3. Predicted consequences of CI deﬁciency in isolatedmouse skeletalmusclemitochondria. The Vmax of CI (x-axis) was gradually reduced from 100% to 1% of that in theWTmodel and
the effect on various steady-state metabolic ﬂuxes, concentrations and other variables was predicted. To facilitate visual inspection, values on the y-axis were expressed as % of their value
at 100% CI activity. (A) Effect of increasing CI deﬁciency on the ﬂux through the OXPHOS system (CI, CII, CIII = CIV, and CV). (B) Similar to panel A, but now for TCA ﬂuxes. (C) Similar to
panel A, but now for exchange ﬂuxes across themitochondrial inner membrane (MIM). (D) Similar to panel A, but now for pyruvate (PYR) and ATP ﬂuxes. (E) Similar to panel A, but now
for ADP andGTP concentration in themitochondrialmatrix. (F) Similar to panel A, but now for TCA cycle intermediates. (G) Similar to panel A, but now for the free concentration of H+, K+
andMg2+ in themitochondrial matrix. (H) Similar to panel A, but now for redox-related parameters. (I) Similar to panel A, but now for mitochondrial membrane potential Δψ (Seemain
text for details).
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